BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2395006)

  • 1. Effect of recombinant interleukin-1 alpha, recombinant interleukin-2, recombinant interferon-beta, and recombinant tumor necrosis factor on subcutaneously implanted adenocarcinoma 755 and Lewis lung carcinoma.
    Iigo M; Nishikata K; Hoshi A
    J Biol Response Mod; 1990 Aug; 9(4):426-30. PubMed ID: 2395006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of interleukin-2 and interferon-beta treatment on lymphocytes in various tumor-bearing mice.
    Iigo M; Nishikata K; Nakajima Y; Moriyama M
    J Biol Regul Homeost Agents; 1989; 3(3):108-11. PubMed ID: 2516403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
    Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
    Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
    McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
    Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
    Iigo M; Nishikata K; Nakajima Y; Moriyama M
    Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.
    McIntosh JK; Jablons DM; Mulé JJ; Nordan RP; Rudikoff S; Lotze MT; Rosenberg SA
    J Immunol; 1989 Jul; 143(1):162-7. PubMed ID: 2499626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
    Cameron RB; McIntosh JK; Rosenberg SA
    Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumor effect of combination therapy with interleukin-2 and polyribonucleotides against adenocarcinoma 755.
    Iigo M; Nakajima Y; Nishikata K; Hoshi A
    J Biol Response Mod; 1989 Apr; 8(2):147-54. PubMed ID: 2786554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
    Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
    Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
    Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL; Stampfl S; Zimmerman RJ
    Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
    McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
    Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
    Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
    J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmented antitumor effect of recombinant human interleukin-1 alpha by indomethacin.
    Nakata K; Kashimoto S; Yoshida H; Oku T; Nakamura S
    Cancer Res; 1988 Feb; 48(3):584-8. PubMed ID: 3257168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of recombinant human interferon-beta and interferon-gamma in combination against human colon cancer cell line in vitro and in nude mice.
    Kondo H; Tanaka N; Naomoto Y; Orita K
    Jpn J Cancer Res; 1987 Nov; 78(11):1258-65. PubMed ID: 3121561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo effects of recombinant human interleukin 6, alone or in combination with local irradiation, on tumor growth in Lewis lung carcinoma-bearing mice.
    Lu L; Shen RN; Broxmeyer HE
    Int J Cell Cloning; 1991 Sep; 9(5):511-20. PubMed ID: 1955739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of murine alpha-, beta-, and gamma-interferons in combination with alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the tumor growth and metastasis of B16 melanoma and Lewis lung carcinoma in mice.
    Sunkara PS; Bowlin TL; Rosenberger AL; Fleischmann WR
    J Biol Response Mod; 1989 Apr; 8(2):170-9. PubMed ID: 2499664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors.
    Nakamura S; Nakata K; Kashimoto S; Yoshida H; Yamada M
    Jpn J Cancer Res; 1986 Aug; 77(8):767-73. PubMed ID: 3093425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
    BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.